Acute dexamethasone administration enhances GH responsiveness to GH releasing peptide-6 (GHRP-6) in man.

Pinto AC, Finamor FE Jr, Lengyel AM

Clinical endocrinology1 Oct 1999Cited by 6 (Europe PMC)

PMID10583306DOI10.1046/j.1365-2265.1999.00792.xPepBankPUB-10583306

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In healthy adults given placebo, the peak GH after GHRP‑6 did not differ from the peak after GHRH.
In plain wordsIn healthy adults given placebo, GHRP‑6 raised the growth hormone peak to a similar level as GHRH.
Peptide
GHRP-6
Outcome
No significant changePeak GH after GHRP-6 versus GHRH, placebo-treated subjects
Study
n = 8
Comparator
GHRH
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microg/kg · intravenousAs given in this study (human).
Source sentences
Summary
In the placebo-treated subjects, mean peak GH (mU/l; mean +/- SE) and AUC (mU.min/l) values after GHRP-6 administration (peak: 43.8 +/- 9.0; AUC: 2262.0 +/- 459. 2) did not differ from those observed after GHRH injection (peak: 49. 8 +/- 12.0; AUC: 2903.4 +/- 872.6).
3 context sentences(design, population, supporting numbers)
Summary · context
One group of subjects received iv GHRP-6 (1 microg/kg), GH-releasing hormone (GHRH; 100 microg), GHRH plus GHRP-6 or saline 3.5 h after oral acute dexamethasone administration (4 mg; at 0600 h).
Summary · context
Sixteen normal subjects (mean age: 29 +/- 3.3 years), with normal BMI (22.4 +/- 2.0 kg/m2), were studied.
Summary · context
Eight subjects received dexamethasone and the other eight were treated with placebo.
Report a problemFND-1058330601
02HumanRandomized controlled trialEfficacy outcome
In healthy adults given placebo, the GH area under the curve after GHRP‑6 did not differ from that after GHRH.
In plain wordsIn healthy adults given placebo, GHRP‑6 gave a similar total growth hormone release as GHRH.
Peptide
GHRP-6
Outcome
No significant changeGH area under the curve after GHRP-6 versus GHRH, placebo-treated subjects
Study
n = 8
Comparator
GHRH
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microg/kg · intravenousAs given in this study (human).
Source sentences
Summary
In the placebo-treated subjects, mean peak GH (mU/l; mean +/- SE) and AUC (mU.min/l) values after GHRP-6 administration (peak: 43.8 +/- 9.0; AUC: 2262.0 +/- 459. 2) did not differ from those observed after GHRH injection (peak: 49. 8 +/- 12.0; AUC: 2903.4 +/- 872.6).
3 context sentences(design, population, supporting numbers)
Summary · context
One group of subjects received iv GHRP-6 (1 microg/kg), GH-releasing hormone (GHRH; 100 microg), GHRH plus GHRP-6 or saline 3.5 h after oral acute dexamethasone administration (4 mg; at 0600 h).
Summary · context
Sixteen normal subjects (mean age: 29 +/- 3.3 years), with normal BMI (22.4 +/- 2.0 kg/m2), were studied.
Summary · context
Eight subjects received dexamethasone and the other eight were treated with placebo.
Report a problemFND-1058330602

Studies that did not test the peptide alone6

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

03HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome
Dexamethasone given before GHRP‑6 significantly increased GH responsiveness to GHRP‑6 compared with placebo.
In plain wordsIn healthy adults, taking dexamethasone first made the growth hormone response to GHRP‑6 larger than after placebo.
Peptide
GHRP-6
Outcome
IncreaseGH responsiveness to GHRP-6 after dexamethasone versus placebo
Study
n = 16
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
When the two groups were compared, a significant increase in GH responsiveness to GHRP-6 was observed after dexamethasone administration compared with placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
One group of subjects received iv GHRP-6 (1 microg/kg), GH-releasing hormone (GHRH; 100 microg), GHRH plus GHRP-6 or saline 3.5 h after oral acute dexamethasone administration (4 mg; at 0600 h).
Summary · context
Sixteen normal subjects (mean age: 29 +/- 3.3 years), with normal BMI (22.4 +/- 2.0 kg/m2), were studied.
Summary · context
Eight subjects received dexamethasone and the other eight were treated with placebo.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1058330607
04HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome
Dexamethasone did not change the GH response to GHRP‑6 plus GHRH compared with placebo.
In plain wordsIn healthy adults, dexamethasone did not change the growth hormone response to GHRP‑6 together with GHRH, compared with placebo.
Peptide
GHRP-6
Outcome
No significant changeGH response to GHRP-6 plus GHRH, dexamethasone versus placebo
Study
n = 16
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
No differences in GH response to GHRH, or to the administration of the two peptides together, were seen between the two groups.
3 context sentences(design, population, supporting numbers)
Summary · context
One group of subjects received iv GHRP-6 (1 microg/kg), GH-releasing hormone (GHRH; 100 microg), GHRH plus GHRP-6 or saline 3.5 h after oral acute dexamethasone administration (4 mg; at 0600 h).
Summary · context
Sixteen normal subjects (mean age: 29 +/- 3.3 years), with normal BMI (22.4 +/- 2.0 kg/m2), were studied.
Summary · context
Eight subjects received dexamethasone and the other eight were treated with placebo.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1058330608
05HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome
In healthy adults given placebo, the combination of GHRP‑6 and GHRH markedly increased GH peak and area under the curve compared with either peptide alone.
In plain wordsIn healthy adults given placebo, GHRP‑6 together with GHRH raised growth hormone far more than either peptide alone.
Peptide
GHRP-6
Outcome
IncreaseGH response to GHRP-6 plus GHRH versus each peptide alone, placebo-treated subjects
Study
n = 8
Comparator
GHRP-6 alone or GHRH alone
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
The association of the two peptides markedly increased GH levels (peak: 172.4 +/- 34.2; AUC: 10393.0 +/- 1894.8) compared with the isolated administration of GHRP-6 or GHRH.
3 context sentences(design, population, supporting numbers)
Summary · context
One group of subjects received iv GHRP-6 (1 microg/kg), GH-releasing hormone (GHRH; 100 microg), GHRH plus GHRP-6 or saline 3.5 h after oral acute dexamethasone administration (4 mg; at 0600 h).
Summary · context
Sixteen normal subjects (mean age: 29 +/- 3.3 years), with normal BMI (22.4 +/- 2.0 kg/m2), were studied.
Summary · context
Eight subjects received dexamethasone and the other eight were treated with placebo.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1058330603
06HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome
In healthy adults given dexamethasone, the peak GH after GHRP‑6 did not differ significantly from the peak after GHRH.
In plain wordsIn healthy adults given dexamethasone, GHRP‑6 and GHRH raised the growth hormone peak to a similar level.
Peptide
GHRP-6
Outcome
No significant changePeak GH after GHRP-6 versus GHRH, dexamethasone-treated subjects
Study
n = 8
Comparator
GHRH
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Mean GH peak and AUC values after GHRP-6 (peak: 78.8 +/- 11.0; AUC: 4114.6 +/- 588.2) and after GHRH administration (peak: 46.8 +/- 16.0; AUC: 3006.8 +/- 1010.0) did not differ significantly in the dexamethasone-treated subjects.
3 context sentences(design, population, supporting numbers)
Summary · context
One group of subjects received iv GHRP-6 (1 microg/kg), GH-releasing hormone (GHRH; 100 microg), GHRH plus GHRP-6 or saline 3.5 h after oral acute dexamethasone administration (4 mg; at 0600 h).
Summary · context
Sixteen normal subjects (mean age: 29 +/- 3.3 years), with normal BMI (22.4 +/- 2.0 kg/m2), were studied.
Summary · context
Eight subjects received dexamethasone and the other eight were treated with placebo.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1058330604
07HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome
In healthy adults given dexamethasone, the GH area under the curve after GHRP‑6 did not differ significantly from that after GHRH.
In plain wordsIn healthy adults given dexamethasone, GHRP‑6 and GHRH gave a similar total growth hormone release.
Peptide
GHRP-6
Outcome
No significant changeGH area under the curve after GHRP-6 versus GHRH, dexamethasone-treated subjects
Study
n = 8
Comparator
GHRH
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Mean GH peak and AUC values after GHRP-6 (peak: 78.8 +/- 11.0; AUC: 4114.6 +/- 588.2) and after GHRH administration (peak: 46.8 +/- 16.0; AUC: 3006.8 +/- 1010.0) did not differ significantly in the dexamethasone-treated subjects.
3 context sentences(design, population, supporting numbers)
Summary · context
One group of subjects received iv GHRP-6 (1 microg/kg), GH-releasing hormone (GHRH; 100 microg), GHRH plus GHRP-6 or saline 3.5 h after oral acute dexamethasone administration (4 mg; at 0600 h).
Summary · context
Sixteen normal subjects (mean age: 29 +/- 3.3 years), with normal BMI (22.4 +/- 2.0 kg/m2), were studied.
Summary · context
Eight subjects received dexamethasone and the other eight were treated with placebo.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1058330605
08HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome
In healthy adults given dexamethasone, GHRP‑6 plus GHRH significantly increased GH peak and area under the curve compared with each peptide alone.
In plain wordsIn healthy adults given dexamethasone, GHRP‑6 together with GHRH raised growth hormone more than either peptide alone.
Peptide
GHRP-6
Outcome
IncreaseGH response to GHRP-6 plus GHRH versus each peptide alone, dexamethasone-treated subjects
Study
n = 8
Comparator
GHRP-6 alone or GHRH alone
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
In this study group, the administration of the two peptides together caused a significant increase in both peak (119.2 +/- 16.0) and AUC values (7377.0 +/- 937.2) compared with the response obtained after each peptide alone.
3 context sentences(design, population, supporting numbers)
Summary · context
One group of subjects received iv GHRP-6 (1 microg/kg), GH-releasing hormone (GHRH; 100 microg), GHRH plus GHRP-6 or saline 3.5 h after oral acute dexamethasone administration (4 mg; at 0600 h).
Summary · context
Sixteen normal subjects (mean age: 29 +/- 3.3 years), with normal BMI (22.4 +/- 2.0 kg/m2), were studied.
Summary · context
Eight subjects received dexamethasone and the other eight were treated with placebo.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1058330606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.